Irrespective of BC subtypes, miR-662 expression levels varied greatly from one cell line to another in luminal [oestrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive] and triple negative (TN) [EGF receptor2 (HER2)-negative, and ER- and PR-negative] BC cells, with the highest expression levels shown by HER2-positive (HER + ) SK-BR3 cells (Fig. 2a). This evidence concerns the gene ERBB2 and breast cancer.